Neurofibromatosis type 2 (NF 2) or schwannomatosis? – Case report study and diagnostic criteria by Radek, Maciej et al.
Case report
Neurofibromatosis type 2 (NF 2)
or schwannomatosis? – Case report study
and diagnostic criteria
Maciej Radek a, Bartłomiej Tomasik a, Maciej Wojdyn a,
Dorota Snopkowska-Wiaderna b, Maciej Błaszczyk a,*, Andrzej Radek a
aDepartment of Neurosurgery and Peripheral Nerve Surgery, Medical University of Łódź, University Hospital
WAM-CSW, Łódź, Poland
bDepartment of Clinical Pathomorphology and Cytopathology, Medical University of Łódź, University Hospital
WAM-CSW, Łódź, Poland
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 0 ( 2 0 1 6 ) 2 1 9 – 2 2 5
a r t i c l e i n f o
Article history:
Received 1 July 2015
Accepted 11 February 2016
Available online 23 February 2016
Keywords:
Craniocervical junction tumor
Neuroﬁbromatosis
Schwannoma
Schwannomatosis
a b s t r a c t
Introduction: Neuroﬁbromatosis type 2 (NF2) and schwannomatosis are entities that may,
due to the similarity of clinical symptoms, cause diagnostic difﬁculties. Incidence rate of
both diseases is similar and estimated between 1:25,000 and 1:40,000. The genes associated
with the development of the aforementioned disorders are located on chromosome 22 and
lay in proxmity. Schwannomatosis is characterized by an incomplete penetrance and the
risk of its transmission to the offspring is signiﬁcantly lower than in the case of NF 2.
Schwannomatosis clinical characteristic is similar to the NF2, however vestibular schwan-
nomas are not present. Therefore the imaging studies evaluated by an experienced radiolo-
gist play a key role in the diagnostic process.
Case report: Forty two-year-old female hospitalized three times because of the tumors of the
spinal canal was admitted to the Department of Neurosurgery and Peripheral Nerve Surgery
in 2008 because of the cervical pain syndrome with concomitant headache. She was
diagnosed with a schwannomatosis, recently distinguished, the third form of neuroﬁbro-
matosis. MRI imaging revealed craniocervical junction tumor. Suboccipital craniectomy
with concomitant C1–C2 laminectomy was done in order to remove the lesion. After the
surgery the patient did not present any deﬁcits in neurological examination and was
discharged from hospital in good general condition.
Conclusions: The patient was diagnosed with schwannomatosis, recently established neuro-
ﬁbromatosis entity which may resemble NF2 clinically. In patients after the age of 30, in
whom we observe multiple schwannomas without the concomitant hearing impairment,
the diagnosis of schwannomatosis is very likely.
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lesion at Th12-L1 level (checkup – 1995).
Fig. 1 – Fascicular arrangement of elongated uniform cells
with small pleomorphism (H + E) (400T).1. Introduction
Schwannomas are one of the most common peripheral nerve
sheath neoplasms. These typically benign tumors occur
spontaneously in a vast majority of cases, yet may also arise
in patients with type 2 neuroﬁbromatosis (NF2) or another
entity called schwannomatosis.
NF2 is a relatively rare, dominantly inherited syndrome
with the incidence rate estimated to be between 1/25,000 and
1/40,000 [1,2]. The identiﬁcation of the NF2 gene, which is
localized on chromosome 22 (22q12) have led us to a better
understanding of this disease. NF2 is a tumor suppressor gene
and its product, merlin, shows similarity to certain cytoskel-
etal proteins. Merlin functions are still not fully described,
although it can bind to actin or a transmembrane CD44
receptor, which is involved in cell interaction with extracellu-
lar matrix [3]. There are multiple diagnostic criteria for NF2 e.g.
the Manchester Criteria, the National Institutes of Health
Criteria, and the Children's Tumor Foundation Criteria [2,4–6].
However, all of them indicate that bilateral vestibular
schwannomas are the hallmark of this condition. Worth
mentioning, the presence of vestibular schwannoma excludes
the diagnosis of schwannomatosis.
Schwannomatosis is a relatively new condition which has
been established over the last few decades. It can be diagnosed
when multiple schwannomas, without cranial nerve VIII
involvement, occur. Thus, experienced radiologist plays a
crucial role in diagnosing schwannomatosis and differentiat-
ing it from NF2. Little is known about the genetic background
of this condition. A family history is present only in 15–25% of
cases [7]. Although somatic mutations of NF2 in the tumor
tissue are quite common in schwannomatosis, NF2 role in the
pathogenesis of this condition has been ruled out by several
authors [8,9]. However other studies revealed germline
mosaicism of the SMARCB1 gene (also called INI-1), which is
localized on chromosome 22 near the NF2 gene [10,11]. Due to
the strong resemblance to the NF2 it is hard to estimate the
prevalence of schwannomatosis but probably it is similar [12].
We present an interesting case report, showing that the
differential diagnosis is not easy and could be a major clinical
challenge.
2. Case report
A 42-year-old patient was admitted to the Department of
Neurosurgery and Peripheral Nerve Surgery in 2008 because of
craniocervical junction tumor. She had the history of three
hospitalizations due to the tumors within the spinal canal. The
family history was negative, patient denied the occurrence of
similar symptoms in relatives. The ﬁrst symptoms, which
were the pain in the thoracic spine followed by spastic paresis
of the lower extremities, occurred in 1994 (the patient was
28-year-old) after the childbirth. During the neurological
consultation the initial diagnosis of multiple sclerosis (MS)
was made. However subsequent thoracic MRI indicated the
tumor at the Th12/L1 level. The laminectomy was performed
and during this procedure the intrameningeal and extraspinal
tumor was resected. Histopathological examination hasshown that it was a schwannoma (Fig. 1). After the operation
the patient did not present any deﬁcits in neurological
examination.
A year later a control thoracic and lumbar MRI was
performed. No changes in the operated region were found
although the study revealed a new, asymptomatic tumor at
the Th12-L1 level (Fig. 2). We decided to perform Th12-L1
laminectomy, during which another schwannoma was
resected. A mild dysesthesia on the outer side of the thigh
on the right side was found during the post-surgery neurolog-
ical examination. The follow-up MRI examination in 1996 did
not reveal any changes (Figs. 3 and 4).
Figs. 5 and 6 – Thoracic and lumbar spine MRI shows hyperintense lesion at Th8-Th9 level (imaging study 2006).
Figs. 3 and 4 – Thoracic and lumbar spine MRI shows no pathologic changes (checkup – 1996).
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 0 ( 2 0 1 6 ) 2 1 9 – 2 2 5 221The patient presented no symptoms until 2006 when she
was admitted to our Department with thoracic pain syndrome
and paraparesis. MRI examination found a Th8-Th9 tumor and
concomitant lesions at Th10-Th11 and Th11-Th12 levels.There was no local recurrence at the site of previous surgery
(Figs. 5 and 6). In smaller tumors we decide to introduce
watchful waiting strategy because they did not compress the
spinal cord. Thus Th8-Th9 hemilaminectomy was performed.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 0 ( 2 0 1 6 ) 2 1 9 – 2 2 5222During this procedure the intrameningeal and extraspinal
tumor was resected. Further histopathological examination
conﬁrmed that it was a schwannoma. The imunohistochem-
ical reaction for S-100 was positive (Fig. 7). After the surgery the
patient did not present any deﬁcits in neurological examina-
tion. The follow-up MRI examination in 2007 did not reveal any
changes (Fig. 8).
In 2008 the patient was admitted again to our Department.
She presented cervical pain syndrome with concomitantFig. 8 – Thoracic and lumbar spine MRI shows no
progression of pathologic changes (checkup – 2007).
Fig. 7 – Positive immunohistochemistry for S100 protein
(200T).headache without deﬁcits in neurological examination.
MRI examination revealed craniocervical junction tumor
(Figs. 9–12). We decided to perform C1-C2 laminectomy and
left side suboccipital craniectomy. The tumor was complete-
ly resected during this procedure. After the surgery the
patient did not present any deﬁcits in neurological exami-
nation. Histopathological examination once again showed
that the tumor was a schwannoma.
In 2009 another follow-up MRI was done and did not ﬁnd
any pathological lesions (Figs. 13 and 14). The patient is under
the care of our clinic to the present day.
3. Discussion
In the reported case we presented the patient with numerous,
slow-growing central nervous system tumors. Histopatholog-
ical examination for each lesion revealed schwannoma
etiology therefore one can assumed that the patient suffered
from NF2. However the tumors of the cranial nerve VIII did not
appear in our patient. The age of the patient is not helpful in
terms of ﬁnal diagnosis, because ﬁrst symptoms of both
disorders may develop in the late twenties. Taking into
consideration abovementioned description a differential
diagnosis between NF2 and schwannomatosis should be
carried out. It should be kept in mind that in 95% of NF2
cases the ﬁrst symptom of a disease is hearing impairment
caused by bilateral vestibular schwannomas [13]. During the
last few decades' ﬁrst reports describing patients who
developed multiple schwannomas not related to NF1 or NF2
appeared in the literature. First mentions of such cases may be
found in the studies from the eighties and [14,15]. Since then,
the term ‘‘schwannomatosis’’ started to exist as a distinct
neuroﬁbromatosis entity [16].
Some researchers considered that schwannomatosis is an ,,
incomplete’’ form or a subcategory of NF2 [17]. According to
others, it is a separate entity – it has been proven that genetic
background of schwannomatosis differs from that of the NF2
[9]. In most cases of schwannomatosis the tumors occurring in
this entity have no distinctive morphologic features in
comparison to sporadic schwannomas. The only discrete
difference is the mosaic expression of BAF47 (INI-1), i.e. the
patchy nuclear immunohistochemical reaction for this protein
in schwannomatosis contrary to uniform positivity in sporadic
schwannomas. In our case this examination was inconclusive
[18].
Since then, new diagnostic criteria, which included
schwannomatosis biology, have been introduced [7]. They
are divided into molecular and clinical part which are
presented below.
3.1. Molecular diagnosis
1. Two or more schwannomas or meningiomas and genetic
studies of at least two tumors showing loss of heterozygos-
ity at chromosome 22 and NF2 mutations. The presence of a
common SMARCB1 mutation deﬁnes SMARCB1-associated
schwannomatosis.
2. One schwannoma or meningioma and a germline patho-
genic SMARCB1 mutation.
Figs. 9–12 – Cervical spine MRI shows hyperintense lesion at craniocervical junction level (imaging study 2008)
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1. Two or more non-intradermal schwannomas (at least one
with pathological conﬁrmation) and the absence of vestib-
ular schwannoma on thin-sliced MRI.
2. One schwannoma or meningioma and affected ﬁrst-degree
relative.
3. Possible diagnosis when two or more non-intradermal
schwannomas (without pathological conﬁrmation) and
chronic pain associated with tumors exist.
According to abovementioned criteria, the exclusion crite-
ria are as follows: germline pathogenic NF2 mutation, fulﬁlled
criteria for NF2, ﬁrst-degree relative with NF2 and schwanno-
mas in radiation ﬁeld only.
In the presented case subsequent lesions had similar
histogenesis which indicates the genetic background. That
might suggest NF2 although vestibular schwannomas were
not present.
When NF2 is suspected the physician should keep in mind
the possibility of schwannomatosis. The clinical course of both
of the diseases might be similar and confusing [19]. Helpfulfeatures to distinguish cases of schwannomatosis from cases
of NF2 include the absence of ocular pathology, ependymomas
and vestibular schwannomas by the age of 30.
Schwannomatosis is a rare disorder which might cause
diagnostic difﬁculties due to its similarity to NF2. We believe
that abovementioned case report is a great example of such
difﬁculties because the ﬁrst lesions appeared in the late third
decade of life, had similar histogenesis while family history
was negative. The diagnosis of schwannomatosis was stated
after the series of MRI's which did not reveal vestibular
schwannomas. By this example we also want to emphasize
that in this group of disease tumors can occur in every part of
human body. When the tumor causes any symptoms it is an
indication for surgery but in case of small, asymptomatic
lesions we can decide to control them regularly by MRI and so
has been done in the reported case.
Patients with schwannomatosis constitute only a small
subgroup of patients with schwannomas. According to
different studies the proportion varies from 3 to 5% [18]. The
vast majority of patients with schwannomatosis is middle-
aged and usually undergo many operations during their adult
life and therefore can be described as a ‘‘high-risk’’ group [12].
Figs. 13 and 14 – Cervical spine MRI shows no pathologic
changes (checkup – 2009).
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 0 ( 2 0 1 6 ) 2 1 9 – 2 2 5224Genetic tests might improve the diagnostic process in those
patients but the results do not affect the decisions taken by the
surgeon because the most crucial issue is thorough diagnostic
imaging.
4. Conclusions
1. In case of multiple schwannomas with concomitant
abscence of vestibular schwannomas and hearing im-
pairment the diagnosis of schwannomatosis should be
taken into consideration.
2. In doubtful cases neuroimaging (MRI) and audiological
testing are helpful to distinguish schwannomatosis from
NF2.3. Despite presented similarities NF-2 and schwannomatosis
are two distinct entities both genetically and clinically.
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